Bisoprolol effectiveness in arterial hypertension and coronary heart disease
Abstract
The authors review the current evidence on the effectiveness of a highly selective b-adrenoblocker bisoprolol in the treatment of arterial hypertension and/or coronary heart disease. The issues of bisoprolol therapy in the specific clinical subgroups of cardiac patients (such as elderly people and smokers) are discussed.
About the Authors
O. D. Ostroumova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
M. L. Maksimov
I.M. Sechenov First Moscow State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
A. M. Rykova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Диагностика и лечение артериальной гипертензии. Ж Сист гиперт 2010; 3: 5-26.
2. Клиническая фармакология. Под ред. В.Г.Кукеса, издание 4. Москва “ГЭОТАР-Медиа” 2008; 392-5.
3. Case DB, Wallace JM, Keim HJ. Behandlung der leichten bis mittelschweren essentiellen Hypertonie mit Bisoprolol. Therapiewoche 1988; 38: 3507
4. Nakanishi T. Effect of bisoprolol hemifumarate on the diurnal variation of blood pressure in patients with essential hypertension. Current Ther Res 1992; 5: 779.
5. Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J 1987;8 (Suppl.M):103-13.
6. Giesecke HG. Three years experience with bisoprolol in the treatment of mild to moderate hypertension. J Cardiovasc Pharmacol 1990; 16 (Suppl 5): 175.
7. Buhler FR, Berglund G, Anderson OK, et al. Double-blind of the cardioselective b-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovas Pharmacol 1986;8 (Suppl.11): 122.
8. Czuriga I, Riecansky I, Bodnar J, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 2003; 17(3): 257-63.
9. Bracchetti D, Gradnik R, Alberti A, et al. A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly. Cardiovasc Drugs Ther 1990; 4: 261.
10. Breed J, Ciampricotti R, Tromp G, et al. Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril. J Cardiovasc Pharmacol 1992; 20: 750.
11. Gosse P, Routaut R, Herreo G, Dallocchio M. Betablockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16 (Suppl 5): 145-50.
12. Zhu LM. The efficacy of once-daily bisoprolol, lacidipine and lisinopril on the 24-hour blood pressure in patients with essential hypertension. J Hypertension 1997; 15 (Suppl 4): 212.
13. Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: Comparative double-blind trial. Eur Heart J 1987; 8 (Suppl M): 65.
14. Gosse P, Gressin V, Clerson P, et al. Comparison of bisoprolol and verapamil in hypertension: influence on left ventricular mass and function — a pilot study. Thérapie 1999; 54: 217.
15. Honoré P. Bisoprolol versus hydrochlorothiazide plus amiloride in essential hypertension, a randomized double-blind study. Eur Heart J 1987; 8 (Suppl M): 95.
16. Bueno J, Amiguet JA, Carasusan J, et al. Bisoprolol vs. chlorthalidone: A randomized, double-blind comparative study in arterial hypertension. J Cardiovasc Pharmacol 1990; 16 (Suppl 5): 189.
17. Cruickshank JM Are we misunderstanding beta-blockers? Int. J. Cardiol. 2007; 120: 10-27.
18. Руководство по артериальной гипертонии. Под ред. Е.И. Чазова, И.Е.Чазовой. Москва Медиа-Медика 2005; 490-508, 616-34.
19. Höffler D, Morgenstern HO. Age dependence of therapy result and risk in the treatment of arterial hypertension? J Cardiovasc Pharmacol 1990; 16 (Suppl 5): 184-8.
20. Prager G, Wagner G. Langzeitbehandlung der essentiellen Hypertonie mit Bisoprolol: Eine multizentrische Monotherapiestudie unter Berücksichtigung des Belastungshochdrucks. Merck KGaA, Darmstadt, 1985.
21. Hanson L. Left ventricuiar hypertrophy. High Blood Pressure 1993; 2(Suppl.I): 2-4.
22. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. Hypertens 1991; 9(Suppl. 2): S3-9.
23. Verdecchia P, Shillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998: 97: 48-54.
24. Motz W, Vogt M, Scheler S, et al. Verbesserung der Koronarreserve nach Hypertrophieregression durch blutdrucksenkende Therapie mit einem b-Rezeptorenblocker. Dtsch Med Wschr 1993; 15: 535-540.
25. De Teresa E. Effects of Bisoprolol on Left Ventricular Hypertrophy in Essential Hypertension. Cardiovasc Drugs Ther 1994; 6: 837.
26. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 tretment studies. JAMA 1996, 275: 1507-13.
27. De Muinck E, Buchner-Moell D, van de Ven LL, Lie KI. Comparative study on the antianginal efficacy and safety of bisoprolol and atenolol a multicenter international randomized study in angina pectoris (MIRSA). J Cardiovasc Pharm 1992; 19: 870-5.
28. Palmer AJ, Neeser K, Paschen B, Cleland JGFEconomic implications of the total ischemic burden bisoprolol study (TIBBS) follow-up. J Med Economics 1998; 1: 263-280.
Review
For citations:
Ostroumova O.D., Maksimov M.L., Rykova A.M. Bisoprolol effectiveness in arterial hypertension and coronary heart disease. Cardiovascular Therapy and Prevention. 2011;10(7):88-92. (In Russ.)
Views:
2982
Email this article 
